INCR
Price
$0.89
Change
-$0.05 (-5.32%)
Updated
Feb 4 closing price
Capitalization
48.9M
84 days until earnings call
Intraday BUY SELL Signals
SXTC
Price
$3.94
Change
-$0.59 (-13.02%)
Updated
Feb 4 closing price
Capitalization
3.36M
Intraday BUY SELL Signals
Interact to see
Advertisement

INCR vs SXTC

Header iconINCR vs SXTC Comparison
Open Charts INCR vs SXTCBanner chart's image
Intercure
Price$0.89
Change-$0.05 (-5.32%)
Volume$161.29K
Capitalization48.9M
China SXT Pharmaceuticals
Price$3.94
Change-$0.59 (-13.02%)
Volume$402.58K
Capitalization3.36M
INCR vs SXTC Comparison Chart in %
INCR
Daily Signal:
Gain/Loss:
SXTC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
INCR vs. SXTC commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCR is a Hold and SXTC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (INCR: $0.89 vs. SXTC: $3.94)
Brand notoriety: INCR and SXTC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: INCR: 151% vs. SXTC: 171%
Market capitalization -- INCR: $48.9M vs. SXTC: $3.36M
INCR [@Pharmaceuticals: Generic] is valued at $48.9M. SXTC’s [@Pharmaceuticals: Generic] market capitalization is $3.36M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCR’s FA Score shows that 1 FA rating(s) are green whileSXTC’s FA Score has 0 green FA rating(s).

  • INCR’s FA Score: 1 green, 4 red.
  • SXTC’s FA Score: 0 green, 5 red.
According to our system of comparison, INCR is a better buy in the long-term than SXTC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCR’s TA Score shows that 5 TA indicator(s) are bullish while SXTC’s TA Score has 4 bullish TA indicator(s).

  • INCR’s TA Score: 5 bullish, 2 bearish.
  • SXTC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, INCR is a better buy in the short-term than SXTC.

Price Growth

INCR (@Pharmaceuticals: Generic) experienced а -3.85% price change this week, while SXTC (@Pharmaceuticals: Generic) price change was -61.93% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.57%. For the same industry, the average monthly price growth was -1.57%, and the average quarterly price growth was +13.49%.

Reported Earning Dates

INCR is expected to report earnings on Apr 30, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.57% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCR($48.9M) has a higher market cap than SXTC($3.36M). INCR has higher P/E ratio than SXTC: INCR (25.48) vs SXTC (0.01). INCR YTD gains are higher at: -1.736 vs. SXTC (-98.358). SXTC has higher annual earnings (EBITDA): -8.33M vs. INCR (-39.54M). SXTC has less debt than INCR: SXTC (1.2M) vs INCR (151M). INCR has higher revenues than SXTC: INCR (273M) vs SXTC (1.54M).
INCRSXTCINCR / SXTC
Capitalization48.9M3.36M1,454%
EBITDA-39.54M-8.33M475%
Gain YTD-1.736-98.3582%
P/E Ratio25.480.01186,621%
Revenue273M1.54M17,750%
Total Cash20.3MN/A-
Total Debt151M1.2M12,552%
FUNDAMENTALS RATINGS
INCR vs SXTC: Fundamental Ratings
INCR
SXTC
OUTLOOK RATING
1..100
450
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
8699
P/E GROWTH RATING
1..100
584
SEASONALITY SCORE
1..100
2950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCR's Valuation (62) in the Servicestothe Health Industry industry is in the same range as SXTC (76) in the Pharmaceuticals Major industry. This means that INCR’s stock grew similarly to SXTC’s over the last 12 months.

INCR's Profit vs Risk Rating (100) in the Servicestothe Health Industry industry is in the same range as SXTC (100) in the Pharmaceuticals Major industry. This means that INCR’s stock grew similarly to SXTC’s over the last 12 months.

INCR's SMR Rating (95) in the Servicestothe Health Industry industry is in the same range as SXTC (98) in the Pharmaceuticals Major industry. This means that INCR’s stock grew similarly to SXTC’s over the last 12 months.

INCR's Price Growth Rating (86) in the Servicestothe Health Industry industry is in the same range as SXTC (99) in the Pharmaceuticals Major industry. This means that INCR’s stock grew similarly to SXTC’s over the last 12 months.

INCR's P/E Growth Rating (5) in the Servicestothe Health Industry industry is significantly better than the same rating for SXTC (84) in the Pharmaceuticals Major industry. This means that INCR’s stock grew significantly faster than SXTC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCRSXTC
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
57%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
72%
N/A
Declines
ODDS (%)
Bearish Trend 8 days ago
81%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
INCR
Daily Signal:
Gain/Loss:
SXTC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SYIEY21.611.06
+5.16%
Symrise Ag
PFSB16.25N/A
N/A
PFS Bancorp, Inc.
NTCYF48.40N/A
N/A
Netcompany Group AS
UEPEN61.99-0.01
-0.02%
Union Electric Co.
URNAF6.93-0.34
-4.61%
Urbana Corp.

INCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCR has been closely correlated with SXTC. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if INCR jumps, then SXTC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
-4.77%
SXTC - INCR
66%
Closely correlated
-13.02%
PRGO - INCR
56%
Loosely correlated
+4.03%
AKBA - INCR
56%
Loosely correlated
-2.84%
ALVO - INCR
54%
Loosely correlated
-2.30%
SHPH - INCR
48%
Loosely correlated
-12.50%
More

SXTC and

Correlation & Price change

A.I.dvisor indicates that over the last year, SXTC has been closely correlated with PRGO. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if SXTC jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SXTC
1D Price
Change %
SXTC100%
-13.02%
PRGO - SXTC
69%
Closely correlated
+4.03%
INCR - SXTC
66%
Closely correlated
-4.77%
AKBA - SXTC
62%
Loosely correlated
-2.84%
ALVO - SXTC
60%
Loosely correlated
-2.30%
HIMS - SXTC
55%
Loosely correlated
-4.46%
More